Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis

Next Previous
Trial Profile

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anselamimab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
  • Indications Amyloid light-chain amyloidosis; Amyloidosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CARES
  • Sponsors Alexion AstraZeneca Rare Disease; Caelum Biosciences

Most Recent Events

  • 13 Aug 2026 According to a Fortress Biotech media release, the company plans to submit the prespecified subgroup analysis from the CARES trials to regulatory authorities and disclosed regulatory submissions in the EU and Japan.
  • 29 May 2026 According to an AstraZeneca media release, results from this trial published in the Journal of Clinical Oncology.
  • 29 May 2026 According to an AstraZeneca media release, results will be presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois (Oral Abstract #7501).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top